Overview: Post-Glucose GH Levels TestIntroduction: The Post-Glucose GH Levels Test measures growth hormone levels after glucose intake to diagnose acromegaly or pituitary disorders, helping manage symptoms like enlarged hands or fatigue. Affecting 1 in 100,000 people, acromegaly poses diagnostic challenges due to gradual onset. Following 2023 Endocrine Society guidelines, it uses immunoassay for high accuracy, supporting endocrinology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in endocrinology.
Other Names: Post-Glucose GH Test, Acromegaly Suppression Assay.
FDA Status: Laboratory-developed test (LDT), meeting endocrinology standards for diagnostic reliability.
Historical Milestone: Post-glucose GH testing began in the 1950s with research by Beck, who linked it to acromegaly. Immunoassay advancements in the 1980s by Siemens improved detection, surpassing earlier bioassays.
Purpose: Measures growth hormone levels to diagnose acromegaly or pituitary disorders, guides surgery or medication, and evaluates patients with enlarged hands, aiming to manage symptoms.
Test Parameters: Growth hormone levels
Pretest Condition: Glucose load required. Collect serum or plasma. Report history of pituitary issues.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL); 2 mL serum in SST. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document enlarged hands or fatigue. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., heart disease), and sample collection risks.
Procedural Considerations: Uses immunoassay to measure levels, requiring labs with analyzers. Results available in 1-2 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or improper glucose load can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: Non-suppressed levels suggest acromegaly, guiding therapy. Early treatment might prevent complications, while untreated cases lead to death. Normal levels may require other tests.
Specialist Consultation: Consult an endocrinologist for interpretation.
Additional Supporting Tests: IGF-1 levels, MRI, or glucose tolerance test to confirm diagnosis.
Test Limitations: Specific to GH suppression; correlation with imaging needed. False negatives possible with early disease.
References: Endocrine Society Guidelines, 2023; Journal of Clinical Endocrinology & Metabolism, Beck P, 2022.
